Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

Disc Medicine is in strong financial shape, advancing key candidates. Find out why IRON stock could be a strong investment ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

MHH team aims to intervene in the autoimmune process and stop the destruction of insulin-producing beta cells in the pancreas ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of 11.1%, reaching US$145.53 billion in 2024 and an impressive US$246.

An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

A simple, noninvasive nasal swab identified a predominance of T2-low asthma subtypes in racial and ethnic minority pediatric ...

Scientists identify a signaling pathway that triggers muscle fatigue in response to nervous system inflammation or infections ...

High CDC20 expression promotes aneuploid cancer cell sensitivity to spindle assembly checkpoint (SAC) inhibition by ...